TORONTO, Sept. 9, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being…


Previous articleNew Psychedelic Entactogens: Designer Drugs Produce Designer Effects
Next articlePain and Psychedelics – Reviewing a Newly Published Paper